Reported 2 days ago
Caris Life Sciences, a biotech firm specializing in AI-driven cancer diagnostics, officially launched its initial public offering on June 18, 2025, by ringing the Nasdaq bell. The company is trading under the ticker CAI, with shares priced at $21, above the initial expectation. Despite significant net losses in previous years, Caris aims to attract investor interest amid a challenging biotech market.
Source: YAHOO